Wegovy Side Effects: 7 Things to Watch For (and How to Manage Them)

Wegovy at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Novo Nordisk
• FDA approved: 2021
• Route: subcutaneous injection (single-dose pen)
• Typical frequency: once weekly
• Half-life: approximately 7 days
• Cash price (US): $1,300-$1,400/month without insurance
• Receptor target: GLP-1 receptor

Most Wegovy side effects are predictable, manageable, and time-limited. The minority that aren't deserve real attention. We separate the two below.

Common Side Effects of Wegovy

The side effects most often reported with Wegovy:

• Nausea — most common in the first 4-8 weeks of titration; usually improves with smaller meals and slower eating.
• Diarrhea — often dose-related; hydration and a temporarily lower-fiber diet can help.
• Vomiting — less common than nausea but can be dose-limiting; report to your clinician if persistent.
• Constipation — common with delayed gastric emptying; fluids, fiber, and movement help.
• Abdominal pain — monitor and discuss with your clinician if it persists or worsens.
• Fatigue — often most prominent during the first weeks of dose escalation.
• Dizziness — monitor and discuss with your clinician if it persists or worsens.

These tend to be dose-related. They are most prominent during dose escalation and typically improve once the body adapts to a steady dose.

Serious Risks

Less common but important:

• Pancreatitis — see incretin class warnings for details. Notify your clinician promptly if relevant symptoms develop.
• Gallbladder disease — see incretin class warnings for details. Notify your clinician promptly if relevant symptoms develop.
• Thyroid C-cell tumors (boxed warning) — see incretin class warnings for details. Notify your clinician promptly if relevant symptoms develop.
• Acute kidney injury — see incretin class warnings for details. Notify your clinician promptly if relevant symptoms develop.
• Suicidal ideation (post-marketing reports) — see incretin class warnings for details. Notify your clinician promptly if relevant symptoms develop.

Wegovy should not be used if you have: personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pregnancy.

How to Manage Common Side Effects

Slow titration. Most GI side effects appear during dose increases. Holding each step for at least four weeks before moving up reduces both severity and dropout rates.

Eat smaller meals. Delayed gastric emptying is a feature of these medications, not a bug. Smaller, more frequent meals are easier to tolerate than three large ones.

Hydrate aggressively. Dehydration worsens nausea and is the most common driver of acute kidney injury reports.

Avoid greasy or fried foods early on. They sit longer and amplify nausea.

Anti-nausea medications. Ondansetron and similar agents are commonly prescribed bridging tools during the first weeks.

Don't lie down right after eating. It worsens reflux symptoms, which are common in early treatment.

For dose-titration questions, see our Wegovy dosage guide.

Side Effects vs. Withdrawal Effects

It's worth distinguishing between side effects (from taking the drug) and withdrawal or rebound effects (from stopping it). For Wegovy, the most relevant rebound concern is appetite returning to baseline and weight regain when the medication is discontinued, which has been documented in trial extension data.

When to Stop and Call Someone

These symptoms warrant prompt clinical evaluation:

• Severe abdominal pain (especially radiating to the back) — possible pancreatitis
• Vision changes
• Signs of allergic reaction (hives, throat tightness, difficulty breathing)
• Severe vomiting or dehydration
• Persistent symptoms that worsen rather than improve

Side Effects in Context

Most people who take Wegovy experience some side effects. Most of those are tolerable and improve with time. The decision to continue is a balance between benefit and tolerance, made together with a clinician.

For people weighing whether Wegovy is the right fit, our Wegovy results page covers the upside.

Bottom Line

If you're considering stopping Wegovy for side effects, talk to your clinician first. The fix is often a small adjustment, not a discontinuation.

Frequently Asked Questions

Related Reading

• What Is Wegovy? Everything You Should Know Before Starting
• Wegovy Results: Realistic Expectations vs. Trial Headlines
• Why Wegovy Costs So Much (and 5 Ways to Pay Less)
• The Wegovy Dose Question Everyone Asks (Finally Answered)
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.
• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.

This page is informational only and is not medical advice. Stop Wegovy and seek medical attention if you experience severe symptoms.